Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Acurx reported a Q2 net loss of $2.3 million, or $0.53 per share, narrowing from a loss of $2.2 million a year prior, while cash position improved to $10.7 million following an April registered direct offering. The company secured FDA guidance on a single Phase 3 study design for its lead candidate ibezapolstat, positioning it for a pivotal trial filing, and received conditional acceptance of the drug's proprietary name.
Key figures
- Rd expenses
- 1071536
- Cash position
- 10656386
- Offering Price
- 3.03
- Shares Offered
- 825085
- Ga expenses
- 1235692
- Warrants shares
- 1650170
- Warrants exercise price
- 2.78
- Proceeds direct offering
- approximately $2.5 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.